drugset / Trial / NCT00376727
Cetuximab in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
27 enrolled
University of California, Davis
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of cetuximab in treating patients with advanced solid tumors.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-11
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 300 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 350 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 400 mg/m2 | Intravenous |